JPH0633269B2 - アルキルアンゲリシン - Google Patents
アルキルアンゲリシンInfo
- Publication number
- JPH0633269B2 JPH0633269B2 JP58195145A JP19514583A JPH0633269B2 JP H0633269 B2 JPH0633269 B2 JP H0633269B2 JP 58195145 A JP58195145 A JP 58195145A JP 19514583 A JP19514583 A JP 19514583A JP H0633269 B2 JPH0633269 B2 JP H0633269B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- alkylangelicin
- alkyl
- dimethyl
- crystallized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- -1 Alkyl angelicin Chemical compound 0.000 title claims description 11
- XDROKJSWHURZGO-UHFFFAOYSA-N isopsoralen Natural products C1=C2OC=CC2=C2OC(=O)C=CC2=C1 XDROKJSWHURZGO-UHFFFAOYSA-N 0.000 title description 16
- MLMVLVJMKDPYBM-UHFFFAOYSA-N pseudoisopsoralene Natural products C1=C2C=COC2=C2OC(=O)C=CC2=C1 MLMVLVJMKDPYBM-UHFFFAOYSA-N 0.000 title description 16
- 229950005143 sitosterol Drugs 0.000 title description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- PFVGXOYZQOJGGR-UHFFFAOYSA-N 6-methylfuro[2,3-h]chromen-2-one Chemical compound C1=CC(=O)OC2=C1C=C(C)C1=C2C=CO1 PFVGXOYZQOJGGR-UHFFFAOYSA-N 0.000 claims description 6
- VWISGRNVMLSLCE-UHFFFAOYSA-N 6,8-dimethylfuro[2,3-h]chromen-2-one Chemical compound C1=CC(=O)OC2=C1C=C(C)C1=C2C=C(C)O1 VWISGRNVMLSLCE-UHFFFAOYSA-N 0.000 claims description 4
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 32
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 22
- 238000011282 treatment Methods 0.000 description 16
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- 230000001028 anti-proliverative effect Effects 0.000 description 9
- 229960000956 coumarin Drugs 0.000 description 8
- 235000001671 coumarin Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 7
- QWQWBHZHRMHXOC-UHFFFAOYSA-N 7-Hydroxy-6-methyl-2H-1-benzopyran-2-one Chemical compound C1=CC(=O)OC2=C1C=C(C)C(O)=C2 QWQWBHZHRMHXOC-UHFFFAOYSA-N 0.000 description 6
- VQDAXVSOTNGSJB-UHFFFAOYSA-N 7-hydroxy-4,6-dimethylchromen-2-one Chemical compound CC1=CC(=O)OC2=C1C=C(C)C(O)=C2 VQDAXVSOTNGSJB-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 6
- 125000004494 ethyl ester group Chemical group 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 206010034972 Photosensitivity reaction Diseases 0.000 description 5
- 208000012641 Pigmentation disease Diseases 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 208000017520 skin disease Diseases 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- TZCWEZGQPBVQDO-UHFFFAOYSA-N (4,6-dimethyl-2-oxochromen-7-yl) acetate Chemical compound O1C(=O)C=C(C)C2=C1C=C(OC(=O)C)C(C)=C2 TZCWEZGQPBVQDO-UHFFFAOYSA-N 0.000 description 4
- NHVDNUKWBWGTLB-UHFFFAOYSA-N (5,6-dimethyl-2-oxochromen-7-yl) acetate Chemical compound O1C(=O)C=CC2=C1C=C(OC(=O)C)C(C)=C2C NHVDNUKWBWGTLB-UHFFFAOYSA-N 0.000 description 4
- AYHSRSLMDCLHKM-UHFFFAOYSA-N (6-methyl-2-oxochromen-7-yl) acetate Chemical compound O1C(=O)C=CC2=C1C=C(OC(=O)C)C(C)=C2 AYHSRSLMDCLHKM-UHFFFAOYSA-N 0.000 description 4
- HBBAUSZULSWDFX-UHFFFAOYSA-N 8-acetyl-7-hydroxy-4,6-dimethylchromen-2-one Chemical compound CC1=CC(=O)OC2=C1C=C(C)C(O)=C2C(=O)C HBBAUSZULSWDFX-UHFFFAOYSA-N 0.000 description 4
- YGNQEADUUIINCM-UHFFFAOYSA-N 8-acetyl-7-hydroxy-5,6-dimethylchromen-2-one Chemical compound C1=CC(=O)OC2=C1C(C)=C(C)C(O)=C2C(=O)C YGNQEADUUIINCM-UHFFFAOYSA-N 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 206010047642 Vitiligo Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 230000001738 genotoxic effect Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 229960004469 methoxsalen Drugs 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 208000007578 phototoxic dermatitis Diseases 0.000 description 4
- 231100000018 phototoxicity Toxicity 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- ZOCNUCYUJBIWAA-UHFFFAOYSA-N 2-(8-acetyl-5,6-dimethyl-2-oxochromen-3-yl)oxyacetic acid Chemical compound CC1=C2C=C(C(OC2=C(C=C1C)C(C)=O)=O)OCC(=O)O ZOCNUCYUJBIWAA-UHFFFAOYSA-N 0.000 description 3
- UUMZSXINPVWGFX-UHFFFAOYSA-N 7-hydroxy-5,6-dimethylchromen-2-one Chemical compound O1C(=O)C=CC2=C(C)C(C)=C(O)C=C21 UUMZSXINPVWGFX-UHFFFAOYSA-N 0.000 description 3
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 3
- UTPWWGUELZENOK-UHFFFAOYSA-N 8-acetyl-7-hydroxy-6-methylchromen-2-one Chemical compound C1=CC(=O)OC2=C1C=C(C)C(O)=C2C(=O)C UTPWWGUELZENOK-UHFFFAOYSA-N 0.000 description 3
- BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 231100000025 genetic toxicology Toxicity 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FNYDIAAMUCQQDE-UHFFFAOYSA-N 4-methylbenzene-1,3-diol Chemical compound CC1=CC=C(O)C=C1O FNYDIAAMUCQQDE-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical class CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 238000005618 Fries rearrangement reaction Methods 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 231100000243 mutagenic effect Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 230000000258 photobiological effect Effects 0.000 description 2
- 231100000760 phototoxic Toxicity 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- MGZOXZPZHVOXQB-UHFFFAOYSA-N (2-oxochromen-7-yl) acetate Chemical compound C1=CC(=O)OC2=CC(OC(=O)C)=CC=C21 MGZOXZPZHVOXQB-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- XMZZKRNRGGMFPM-UHFFFAOYSA-N 2-sulfonylacetaldehyde Chemical compound O=CC=S(=O)=O XMZZKRNRGGMFPM-UHFFFAOYSA-N 0.000 description 1
- LFOMIXFRGAIFQF-UHFFFAOYSA-N 3-methylfuro[2,3-h]chromen-2-one Chemical compound C1=C2OC=CC2=C2OC(=O)C(C)=CC2=C1 LFOMIXFRGAIFQF-UHFFFAOYSA-N 0.000 description 1
- RCNCKKACINZDOI-UHFFFAOYSA-N 4,5-dimethylbenzene-1,3-diol Chemical compound CC1=CC(O)=CC(O)=C1C RCNCKKACINZDOI-UHFFFAOYSA-N 0.000 description 1
- VVZYOVZUPIFCCR-UHFFFAOYSA-N 8-methylfuro[2,3-h]chromen-2-one Chemical compound C1=CC(=O)OC2=C1C=CC1=C2C=C(C)O1 VVZYOVZUPIFCCR-UHFFFAOYSA-N 0.000 description 1
- NHOICFAHZSXGJY-UHFFFAOYSA-N 9-methylfuro[2,3-h]chromen-2-one Chemical compound C1=CC(=O)OC2=C3C(C)=COC3=CC=C21 NHOICFAHZSXGJY-UHFFFAOYSA-N 0.000 description 1
- FLBIFKGRMOTBMO-UHFFFAOYSA-N BrCC(=O)OCC.CC(=O)C Chemical compound BrCC(=O)OCC.CC(=O)C FLBIFKGRMOTBMO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- 238000005821 Claisen rearrangement reaction Methods 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 241000255890 Galleria Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229950008352 promoxolane Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT84148A/82 | 1982-10-18 | ||
| IT84148/82A IT1165797B (it) | 1982-10-18 | 1982-10-18 | Procedimento di preparazione di alchilangelicine esenti da psoraleni ed alchilangolicine ottenute col procedimento |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59104387A JPS59104387A (ja) | 1984-06-16 |
| JPH0633269B2 true JPH0633269B2 (ja) | 1994-05-02 |
Family
ID=11324788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58195145A Expired - Lifetime JPH0633269B2 (ja) | 1982-10-18 | 1983-10-18 | アルキルアンゲリシン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5001147A (en, 2012) |
| JP (1) | JPH0633269B2 (en, 2012) |
| AT (1) | AT384810B (en, 2012) |
| AU (1) | AU559082B2 (en, 2012) |
| CA (1) | CA1228860A (en, 2012) |
| CH (1) | CH662566A5 (en, 2012) |
| DE (1) | DE3337207A1 (en, 2012) |
| ES (1) | ES8608523A1 (en, 2012) |
| FR (1) | FR2534585B1 (en, 2012) |
| GB (1) | GB2128997B (en, 2012) |
| IT (1) | IT1165797B (en, 2012) |
| ZA (1) | ZA837585B (en, 2012) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1967185A1 (en) * | 1999-12-23 | 2008-09-10 | Pfizer Products Inc. | Hydrogel-driven drug dosage form |
| CN101287493A (zh) * | 2005-08-18 | 2008-10-15 | 根马布股份公司 | 采用cd4结合肽和辐射的疗法 |
| ITVE20070005A1 (it) | 2007-01-25 | 2008-07-26 | Associazione Veneta Per La Lotta Alla Talassemia | Farmaco per la cura della talassemia, dell'anemia falciforme e di tutte le altre forme di anemia trattabili con questo, metodo di attivazione del farmaco, composizione farmaceutica avente come principio attivo il farmaco e metodo fotochemioterapico u |
| CN102177162B (zh) | 2008-10-21 | 2015-02-11 | 花王株式会社 | Nfat信号抑制剂以及育发剂 |
| CN105832720B (zh) * | 2016-05-03 | 2019-04-05 | 中国科学院新疆理化技术研究所 | 一种补骨脂素类化合物的用途 |
| CN116554190A (zh) * | 2023-05-06 | 2023-08-08 | 河南中烟工业有限责任公司 | 一种香柑醇的合成方法及应用 |
| CN116554191A (zh) * | 2023-05-06 | 2023-08-08 | 河南中烟工业有限责任公司 | 一种香柑内酯的合成方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI59598C (fi) * | 1977-10-03 | 1981-09-10 | Star Oy Ab | Nytt foerfarande foer framstaellning av i 9-staellningen eventuellt metoxisubstituerade 7h-furo(3,2-g)(1)bensopyran-7-oner |
| JPS55124775A (en) * | 1979-03-13 | 1980-09-26 | Elder Thomas C Inc | Alphaalower alkylfurocoumarin manufacture and intermediate oftained therefrom |
| US4216154A (en) * | 1979-03-15 | 1980-08-05 | Thomas C. Elder, Inc. | Process for making α-loweralkylfurocoumarins |
| IT1166343B (it) * | 1979-08-20 | 1987-04-29 | Francarosa Baccichetti | Furocumarina per la fotochemioterapia della fsoriasi e di altre malattie cutanee ad essa sensibili |
-
1982
- 1982-10-18 IT IT84148/82A patent/IT1165797B/it active
-
1983
- 1983-10-11 GB GB08327200A patent/GB2128997B/en not_active Expired
- 1983-10-12 ZA ZA837585A patent/ZA837585B/xx unknown
- 1983-10-13 DE DE19833337207 patent/DE3337207A1/de active Granted
- 1983-10-13 AU AU20141/83A patent/AU559082B2/en not_active Ceased
- 1983-10-14 CH CH5624/83A patent/CH662566A5/it not_active IP Right Cessation
- 1983-10-17 AT AT0370383A patent/AT384810B/de not_active IP Right Cessation
- 1983-10-17 CA CA000439121A patent/CA1228860A/en not_active Expired
- 1983-10-18 ES ES526910A patent/ES8608523A1/es not_active Expired
- 1983-10-18 FR FR8316604A patent/FR2534585B1/fr not_active Expired
- 1983-10-18 JP JP58195145A patent/JPH0633269B2/ja not_active Expired - Lifetime
-
1988
- 1988-05-16 US US07/194,180 patent/US5001147A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FR2534585A1 (fr) | 1984-04-20 |
| FR2534585B1 (fr) | 1986-12-19 |
| ZA837585B (en) | 1984-06-27 |
| DE3337207A1 (de) | 1984-04-19 |
| AT384810B (de) | 1988-01-11 |
| ATA370383A (de) | 1987-06-15 |
| ES8608523A1 (es) | 1986-07-16 |
| CA1228860A (en) | 1987-11-03 |
| IT1165797B (it) | 1987-04-29 |
| DE3337207C2 (en, 2012) | 1991-12-19 |
| GB2128997A (en) | 1984-05-10 |
| AU559082B2 (en) | 1987-02-19 |
| US5001147A (en) | 1991-03-19 |
| GB8327200D0 (en) | 1983-11-09 |
| IT8284148A0 (it) | 1982-10-18 |
| CH662566A5 (it) | 1987-10-15 |
| JPS59104387A (ja) | 1984-06-16 |
| AU2014183A (en) | 1984-05-03 |
| ES526910A0 (es) | 1986-07-16 |
| GB2128997B (en) | 1985-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3031164C2 (de) | Angelicine enthaltende Arzneimittel, Angelicine als solche sowie Verfahren zu deren Herstellung | |
| US4294822A (en) | 5-Aminoalkyl-4,4,8-trialkylpsoralens | |
| US5198552A (en) | Indole derivative having antiviral, interferon-inducing and immunomodulatory effects | |
| JP3613599B2 (ja) | イミノクロリンアスパラギン酸誘導体 | |
| JPH0633269B2 (ja) | アルキルアンゲリシン | |
| CA1141766A (en) | 8-aminoalkyl-4-alkylpsoralens | |
| CA1169081A (en) | 8-aminoalkyl-4-alkylisopsoralens | |
| FR2464959A1 (fr) | Nouveaux 4,5',8-trialkylpsoralenes, leur procede de production et composition pharmaceutique les contenant | |
| JPS6144843B2 (en, 2012) | ||
| EP0088023B1 (fr) | Pyrido(3',4':4,5) furo(3,2-g) coumarines ou pyrido(3,4-h) psoralènes,obtention, applications en cosmétologie et à titre de médicaments, et compositions cosmétiques et pharmaceutiques les contenant | |
| CN116655654A (zh) | 一类n-取代苯基-2-吡啶酮内过氧化物及其应用 | |
| US5179217A (en) | Method of preparing photochemotherapic alkylangelicin compounds | |
| JPS58103377A (ja) | ２−フエニル−モルホリン誘導体およびこの化合物を含有する抗うつ剤 | |
| CN117143028B (zh) | 一类羟苯基哒嗪曼尼希碱类化合物及其制备方法和用途 | |
| EP1569642B1 (fr) | Utilisation de la canthin-6-one, des extraits de plantes la contenant et de ses derives dans le traitement des trypanosomiases | |
| US5753695A (en) | Flavilium compounds and method of using | |
| JPH0246589B2 (en, 2012) | ||
| KR900000383A (ko) | 신규 화합물 | |
| Birman et al. | Hypotensive activity of Crataegus tanacetifolia | |
| CN120365226A (zh) | 一类水杨酸类衍生物及其用途 | |
| JPH01283218A (ja) | 筋肉弛緩剤 | |
| CH665642A5 (fr) | Derives de l'aminomethyle-6 furo-(3,4-c)-pyridine, leur preparation et compositions therapeutiques en contenant. | |
| RU96101227A (ru) | Способ защиты растений сахарной свеклы от болезней | |
| Dressler | Pharmaceuticals, Over-the-Counter Medications, and Diagnostic Aids | |
| JPH02101074A (ja) | ６‐アロイル‐置換３，４‐ジヒドロ‐２ｈ‐ベンゾピランおよびその製造方法 |